These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 7460388)
1. Antibody-dependent haemolytic activity of human leukaemic cells. Holm G; Björkholm M; Böttiger B; Mellstedt H; Pettersson D; Simonsson-Lindemalm C Clin Exp Immunol; 1980 Oct; 42(1):121-6. PubMed ID: 7460388 [TBL] [Abstract][Full Text] [Related]
2. Antibody-dependent cellular cytotoxicity of leukaemic blast cells and neutrophils from patients with acute myelogenous leukaemia. Dallegri F; Holm G; Gahrton G Clin Exp Immunol; 1982 Feb; 47(2):414-8. PubMed ID: 6951665 [TBL] [Abstract][Full Text] [Related]
3. [Antibody-dependent cellular cytotoxicity (AAZZ) against leukemia cells--K-cell activity of human leukocytes]. Thränhardt H; Zintl F; Plenert W Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(6):824-40. PubMed ID: 6162750 [TBL] [Abstract][Full Text] [Related]
4. Human monocyte-mediated antibody dependent cytotoxicity to K-562 cells: an electron microscopic study. Espevik T; Hammerstrøm J Acta Pathol Microbiol Immunol Scand C; 1983 Jun; 91(3):211-9. PubMed ID: 6880752 [TBL] [Abstract][Full Text] [Related]
5. The antibody-independent cytotoxic activity of normal circulating human leucocytes. I. Lysis of target cells by monocytes and neutrophils in a non-phagocytic pathway. Banerjee D; Fernando L; Sklar S; Richter M Immunology; 1981 Sep; 44(1):97-107. PubMed ID: 7275189 [TBL] [Abstract][Full Text] [Related]
6. Studies on the composition and elimination of circulating immune complexes in leukaemia. Hollán SR; Füst G; Mód A; Puskás E; Nguyen Chi Phi Haematologia (Budap); 1980; 13(1-4):263-82. PubMed ID: 7250813 [TBL] [Abstract][Full Text] [Related]
7. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808 [TBL] [Abstract][Full Text] [Related]
8. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. Lefebvre ML; Krause SW; Salcedo M; Nardin A J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334 [TBL] [Abstract][Full Text] [Related]
9. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412 [TBL] [Abstract][Full Text] [Related]
10. Decreased antibody-dependent cellular cytotoxicity in various types of leukaemia in man. Jakóbisiak M; Janowska-Wieczorek A; Dobaczewska H; Kańtoch M; Marczak M; Oblakowski P; Lasek W; Sosnowska M Scand J Haematol; 1981 Sep; 27(3):181-5. PubMed ID: 6947403 [TBL] [Abstract][Full Text] [Related]
11. Decreased phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) in type-1 diabetes. Sabioncello A; Rabatic S; Kadrnka-Lovrencic M; Oberiter V; Dekaris D Biomedicine; 1981 Dec; 35(7-8):227-9. PubMed ID: 7346070 [TBL] [Abstract][Full Text] [Related]
12. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480 [TBL] [Abstract][Full Text] [Related]
13. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742 [TBL] [Abstract][Full Text] [Related]
14. Expression of blood group-like antigens on the T lymphocytes of acute leukaemia patients in remission. Pullen S; Hersey P Clin Exp Immunol; 1980 Feb; 39(2):403-10. PubMed ID: 6966993 [TBL] [Abstract][Full Text] [Related]
15. [Phagocytic ability of blast cells in acute leukemia]. Kaiser A Acta Haematol Pol; 1979; 10(1):46-50. PubMed ID: 285562 [TBL] [Abstract][Full Text] [Related]
16. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Belov L; Huang P; Chrisp JS; Mulligan SP; Christopherson RI J Immunol Methods; 2005 Oct; 305(1):10-9. PubMed ID: 16125720 [TBL] [Abstract][Full Text] [Related]
17. Cellular and humoral cytotoxicity in patients with leukaemia and preleukaemia. II. Oncovirus specificity of the reaction. Szabó B; Tóth FD; Váczi L; Réthy A; Kiss A; Rák K Acta Microbiol Hung; 1984; 31(4):365-72. PubMed ID: 6085606 [TBL] [Abstract][Full Text] [Related]
18. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
19. Phagocytic potential of leukaemic B-lymphocytes. Catovsky D; Sperandio P; O'Brien M; Cherchi M; Galton DA Scand J Haematol; 1977 Aug; 19(2):211-6. PubMed ID: 302476 [TBL] [Abstract][Full Text] [Related]
20. Studies on phagocytosis in leukaemia. III. Phagocytosis inhibiting factor in sera of leukaemic patients. Melezyńska-Matej M; Grzybek-Hrynewicz K; Kotlarek-Haus S; Kaiser A Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):559-66. PubMed ID: 6170550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]